WKWojciech Kuncman

Wojciech Kuncman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wojciech Kuncman has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification

    by Dorota Jesionek-Kupnicka, Marcin Braun, Tadeusz Robak, Wojciech Kuncman, Radzislaw Kordek

    High-grade B-cell lymphomas (HGBLs) comprise a new entity in the revised 2016/2017 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. The diagnosis of HGBL encompasses histopathology and immunohistochemistry, with additional molecular examination of the BCL2/MYC or BCL6/MYC rearrangement status. The aim of the study was to summarize our experience in the histopathological and immunohistochemical diagnosis of patients with aggressive B-cell lymphomas according to the revised 2016/2017 WHO classifications. We reviewed our single-institution experience with accurate diagnoses of HGBL and diffuse large B-cell lymphoma (DLBCL) using the available histopathological and immunohistochemical tools. The timeframe was from January 1, 2017 to April 18, 2018. Out of 265 patients, 217 (81.9%) were diagnosed with DLBCL, 43 (16.2%) with HGBL/DLBCL and 5 (1.9%) with not otherwise specified HGBL (HGBL-NOS). Regarding concurrent expression of MYC and BCL2 and/or BCL6 (double expressors (DE) and triple expressors (TE)), more DE and TE cases were found in the HGBL/DLBCL group than in the DLBCL group (25.53% vs 8.47%, p < 0.001, for DE cases and 55.32% vs 6.21%, p < 0.001, for TE cases). All 48 (100.00%) of the HGBL-NOS and HGBL/DLBCL patients, and 26 (11.98%) of the DLBCL-DE/TE cases were recommended for molecular analysis. Our findings show that a comprehensive histopathological and immunohistochemical examination may identify potential HGBL cases. This study emphasizes the need to introduce a suitable molecular examination for patients with HGBL morphology and/or double/triple expression of BCL2/BCL6/MYC proteins.


  • Evaluation of selected molecular parameters in two types of endometrial cancer.

    by Janina Markowska, Anna Markowska, Pawel Knapp, Monika Pawalowska, Jakub Zurawski, Stefan Sajdak, Andrzej Bienkiewicz, Anita Olejek, Wiesława Bednarek, Anna Grybos, et al.

    E17118 Background: Multiple factors linked to etiology, clinical course and prognosis in two types of endometrial cancer (endometrioid type I and non-endometrioid type II cancer) have been recognised .These include alterations in concentrations of estrogen and progesterone hormones, mutations in MMR (mismatch repair) genes, PTEN, TP53, beta-catenin, disturbed signalling pathways (e.g. PI3K/AKT). However, in several studies, including the data of Epidemiology of Endometrial Cancer Consortium, endometrial cancers and those of type II (serous carcinoma and clear-cells carcinoma) in particular proved to be more heterogenous than expected (1),(2),(3). Methods: The study manifested a multi-centre character. Using sections of paraffin-embedded preparations and immunocytochemistry with application of specific antibodies, in 115 patients with EC type I and in 31 patients with EC type II, the expression of ER ß1, ER ∂, PR and BRCA1 was estimated. Results: Expression of ER ß1 was augmented in USC (type II ), in cancers of a poor differentiation(G3), it was more pronounced in cancers of an increased clinical advancement according to FIGO. Expression of ER ∂ was detected in the endometrioid type I cancer manifesting good histological differentiation (G1or G2) and a low clinical degree of advancement according to FIGO. In over 50% cases of EC type II a mutation was detected in BRCA1, associated with a decreased expression of ER ∂. Conclusions: An augmented expression of ER ß1 in EC was linked to poor prognosis in type II EC. Higher expression of ER ∂ in type I EC of increased maturity was associated with a good prognosis. It seems that type II EC is partially connected to BRCA1 mutation.